About EicOsis

Bringing New Hope
to Pain Patients

Chronic Pain Affects 100 Million Americans

At EicOsis, our mission is to develop new effective and safe oral medicines to help people and companion animals suffering from pain. We are committed to improving the lives of those suffering from pain, helping them feel themselves again. Contact us.

Our Leadership Team
Dr. Bruce Hammock, Founder, EicOsis

Dr. Bruce Hammock

Founder and CEO

Dr. Hammock is a Distinguished Professor at the University of California, Davis. Dr. Hammock is an elected member of the National Academy of Sciences, US (1999). He has over 30 years of extensive experience in the field of eicosanoids that yielded over 1000 publications and 100 issued patents on synthesis, pharmacology and biological action of eicosanoids and soluble epoxide hydrolase inhibitors.

Dr. William Schmidt, Clinical Development, EicOsis

Dr. William Schmidt

Clinical Development

Dr. Schmidt is head of NorthStar Consulting, LLC, which specializes in providing advice on preclinical and clinical studies of novel analgesic drugs. He is the Parliamentarian and a Past-President of the Eastern Pain Association and has over 25 years of pharmaceutical experience specifically in the development of novel analgesic drugs. Dr. Schmidt currently sits on Scientific Advisory Boards of 4 biotech companies.

Dr. Alan Buckpitt

Vice President of Pharmacology

Dr. Buckpitt is an emeritus Professor of Pharmacology at the University of California, Davis. For over 25 years, Dr. Buckpitt has specialized in the areas of pharmacokinetics as well as absorption, distribution, metabolism, and excretion. He received early training as a postdoctoral fellow in both the Laboratory of Chemical Pharmacology, NHLBI (with Dr. Jerry Mitchell) and the Laboratory of Clinical Pharmacology, National Cancer Institute (with Dr. Michael Boyd).

Dr. Karen Wagner, Principal Scientist, EicOsis

Dr. Karen Wagner

Principal Scientist

Dr. Wagner is a pharmacologist with extensive experience in investigating the role of lipid mediators in neurobiology. She has expertise with animal behavior and in vivo experimentation and leads the preclinical research of the role of sEH inhibition in pain.

Dr. Sung Hee Hwang, EicOsis, Principal Chemist

Dr. Sung Hee Hwang

Principal Chemist

Dr. Hwang is a synthetic chemist with expertise in the design, synthesis, and characterization of small molecules in medicinal chemistry. He leads the development of highly potent inhibitors of epoxide hydrolase and cyclooxygenase enzymes.

Dr. Jun Yang, EicOsis

Dr. Jun Yang

Principal Scientist

Dr. Yang is an analytical chemist with expertise in the DMPK and analyses of small molecules in medicinal chemistry. He leads the research on DMPK of highly potent inhibitors of epoxide hydrolase and biomarker assessment.

Dr. Cindy McReynolds, EicOsis, Sr. Project Mgr

Cindy McReynolds

Senior Project Manager

Ms. McReynolds is a Senior Project Manager who has previously managed preclinical efforts for start-up and semi-virtual biotech companies like Miikana. She also managed the research efforts from IND-enabling studies through Phase II clinical trials at Arete Therapeutics.

Dr. Irene Cortés-Puch, Clinical Scientist, EicOsis

Dr. Irene Cortés-Puch

Clinical Scientist

Dr. Cortés-Puch is a critical care medicine physician and researcher with expertise in study design, intensive care medicine and translational medicine. She spent 5 years conducting translational research at the National Institutes of Health and is currently a scientist at UC Davis Division of Pulmonary and Critical Care Medicine.

Picture of Glenn Croston, COO

Dr. Glenn Croston

Chief Operating Officer

Glenn Croston is a PhD biologist with over 25 years of drug discovery experience helping to progress novel compounds into the clinic in a wide range of therapeutic areas, including pain therapeutics. Glenn has worked in drug research and development from startup biotech to established pharmaceutical companies, from the lab bench to clinical development, translating science into drugs that make a meaningful difference for patients.